• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Almac Group appoints Professor Tom Moody as technology VP

Almac Group appoints Professor Tom Moody as technology VP

December 19, 2016
CenterWatch Staff

Almac Group, a global contract development and manufacturing organization, has announced the appointment of Professor Tom Moody to the position of VP Technology Development and Commercialization within Almac Sciences. 

Tom joined Almac in October 2001, moved into management in 2008 and has held the position of senior manager for the last four years, operating in his role as head of Biocatalysis and Isotope Chemistry. Over this time, he has led the development of Almac Sciences’ Biocatalysis Technology platform which has seen rapid growth and has multiple applications across a range of project scales and industry sectors. 

In the last year, he played an integral role in the integration of Arran Chemical Company into Almac Sciences and ensured smooth transfer of Biocatalysis manufacturing projects from Craigavon to the Arran site in Athlone, Ireland. 

In his new role, Tom will be responsible for the development and application of platform technologies within both the Sciences and Arran businesses, in addition to supporting and directing commercialisation of new technology. He will have direct operational responsibility for the Biocatalysis and Isotope Chemistry businesses and the R&D function within Arran. 

Tom will report directly to Dr Stephen Barr, president & MD, Almac Sciences. 

Barr said, “Tom’s considerable expertise and experience within biocatalysis and chemical synthesis has been crucial in developing the Sciences, and more recently, Arran businesses. In addition, his ability to form incredibly strong relationships with our clients has been critical to the growth and success of these particular service offerings. I am delighted to announce Tom’s promotion to VP and wish him every success in his new role.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing